Unibios Holdings (ATH:BIOSK) 5-Year EBITDA Growth Rate: 27.90% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATH:BIOSK Unibios Holdings SA ATH:BIOSK
62 GF Score
Price €2.72
GF Value €1.48
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Unibios Holdings 5-Year EBITDA Growth Rate?

Unibios Holdings ATH:BIOSK -0.91% 62 5-Year EBITDA Growth Rate is 27.90% as of Dec. 2025. GuruFocus rates ATH:BIOSK with a GF Score™ of 62/100 and a GF Value™ of €1.48 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Unibios Holdings's EBITDA per Share for the six months ended in Dec. 2025 was €0.05.

During the past 12 months, Unibios Holdings's average EBITDA Per Share Growth Rate was 36.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 16.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 27.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Unibios Holdings was 58.50% per year. The lowest was -35.10% per year. And the median was -9.80% per year.


Unibios Holdings  (ATH:BIOSK) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Unibios Holdings 5-Year EBITDA Growth Rate Related Terms


ATH:BIOSK vs VLTO, ZWS, CECO: 5-Year EBITDA Growth Rate Comparison

For the Pollution & Treatment Controls subindustry, Unibios Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unibios Holdings 5-Year EBITDA Growth Rate vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Unibios Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Unibios Holdings's 5-Year EBITDA Growth Rate falls into.


ATH:BIOSK
62GF Score
Unibios Holdings SA ATH:BIOSK
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unibios Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 27.90% mean?
Unibios Holdings (ATH:BIOSK) has a 5-Year EBITDA Growth Rate of 27.90% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Unibios Holdings and its competitors.
Is Unibios Holdings' 5-Year EBITDA Growth Rate too high?
Unibios Holdings' current 5-Year EBITDA Growth Rate is 27.90%. Overall, Unibios Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unibios Holdings' 5-Year EBITDA Growth Rate compare to VLTO and ZWS?
Unibios Holdings' 5-Year EBITDA Growth Rate of 27.90% can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for an Industrial Products company?
A good 5-Year EBITDA Growth Rate depends on the Industrial Products industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Unibios Holdings and its competitors. Unibios Holdings's current 5-Year EBITDA Growth Rate is 27.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unibios Holdings stock overvalued right now?
Based on GuruFocus' analysis, Unibios Holdings (ATH:BIOSK) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.48, compared to a current price of €2.72 — trading 83.8% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 27.90%. Unibios Holdings' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Unibios Holdings (ATH:BIOSK), the current 5-Year EBITDA Growth Rate is 27.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unibios Holdings (ATH:BIOSK) Overvalued in 2026?

Based on GuruFocus' analysis, Unibios Holdings stock appears to be overvalued. The current stock price of €2.72 is trading 83.8% above its estimated GF Value™ of €1.48. GuruFocus considers Unibios Holdings to be Significantly Overvalued.

Key valuation signals for ATH:BIOSK:

  • 5-Year EBITDA Growth Rate: 27.90%
  • GF Value™: €1.48 vs. price of €2.72 (83.8% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the ATH:BIOSK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Unibios Holdings Business Description

Other Exchanges BEXQ:Germany
Address 1st and 18th Street, Ano Liosia, GRC, 13341
Unibios Holdings SA, through its subsidiaries, provides technologies for the responsible use of water and energy. Its activities include the treatment, filtration, water management, heating, and air conditioning, combined with energy saving.
62GF Score

Get the complete analysis for ATH:BIOSK

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€1.48
GF Value